For the study, researchers used data compiled by health IT company Concert Genetics. They examined the test catalog database for March 2014 to August 2017 to determine genetic testing trends and the genetic testing claims database for January 2014 to December 2016 to determine commercial insurers’ genetic spending.
Among the 75,000 genetic tests identified, most were single-gene tests. It also found rapid growth in genetic testing, with about 10 new tests coming about each day.
As far as genetic spending, prenatal tests made up 33 to 43 percent of spending from 2014-16, according to the study. The next highest percentage of spending was hereditary cancer tests (approximately 30 percent).
“Our results provide insights for those interested in assessing genetic testing markets, test usage, and health policy implications, including current debates over the most appropriate regulatory and payer coverage mechanisms,” the study’s authors concluded.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
